MedPath

Role of Tzanck Smear in Determining Pemphigus Vulgaris Disease Activity

Conditions
Pemphigus Vulgaris
Interventions
Diagnostic Test: Tzanck smear
Registration Number
NCT05338112
Lead Sponsor
Istanbul Medeniyet University
Brief Summary

Aim: Pemphigus vulgaris (PV) is a rare, life-threatening autoimmune bullous disease that can involve the skin and mucous membranes, characterized by intraepidermal bullae and eroded lesions caused by rupture of the bullae. The aim of this study is to research the relationship of the findings obtained with Tzanck smear, which is an inexpensive and easy method, with disease activity and its prognostic importance in the clinical course in PV patients.

Material and Methods: Pemphigus patients who visited to Goztepe Prof. Dr. Suleyman Yalcın City Hospital, Dermatology Clinic will be included in our study. Pemphigus disease area index (PDAI), Tzanck smear findings from the lesions and desmoglein levels during routine follow-up of patients with pemphigus vesicle/bulla/erosion will be evaluated. In the evaluation of Tzanck smear preparations, the entire slide will be scanned, acantholytic cell count performed and scored 1 to 4 accordingly (1 point: 1-3 cells, 2 points: 4-10 cells, 3 points:11-20, 4 points: \>21 cells or cell clusters). Anti-desmoglein antibody levels will be analyzed by using enzyme-linked immunosorbent assay (ELISA) method.

Detailed Description

Not available

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
50
Inclusion Criteria
  • Clinical, histopathological and immunological diagnosis of pemphigus vulgaris
  • Must be active bullae or erosion at any stage of the disease
Exclusion Criteria
  • Patients with uncertain diagnosis of pemphigus vulgaris
  • Eroded lesions due to causes other than pemphigus vulgaris (such as herpes in the oral mucosa, candida infection)

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Arm && Interventions
GroupInterventionDescription
Patients with active pemphigus lesionsTzanck smear-
Primary Outcome Measures
NameTimeMethod
The number of acantholytic cells1or 2 months

Tzanck smear slides will be entirely scanned, acantholytic cell count will be performed and scored 1 to 4 accordingly (1 point: 1-3 cells, 2 points: 4-10 cells, 3 points:11-20, 4 points: \>21 cells or cell clusters).

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Istanbul Medeniyet University

🇹🇷

Istanbul, Turkey

© Copyright 2025. All Rights Reserved by MedPath